Python Blood May Point To A New Weight Loss Drug, And Humans Already Make The Key Ingredient

Scientists Were Studying Snake Blood For Other Reasons. What They Found Could Change Obesity Treatment.

Burmese pythons are among the most extreme eaters on the planet. In the wild, they can go without food for over a year, then swallow prey equal to their entire body weight in a single sitting. That biological extreme made them the perfect place to look for a natural signal the body sends after a meal to stop eating. For this study, researchers fed the snakes a standardized meal amounting to about a quarter of their body weight, enough to trigger a dramatic chemical response in the blood.

Researchers at Stanford University, the University of Colorado Boulder, and Baylor College of Medicine found exactly that. Working from python blood, they identified a molecule called para-tyramine-O-sulphate, or pTOS, that surges after a meal and appears to help signal fullness in the brain. In obese mice, daily doses of pTOS cut food intake and triggered measurable weight loss. Stanford University has already filed a provisional patent on pTOS for the treatment of obesity and related metabolic conditions.

Published in the journal Nature Metabolism, the work represents a rare case of a reptile pointing scientists toward a potential human therapy.

How Scientists Used Python Blood to Find a New Appetite Suppressant

Researchers collected blood from Burmese pythons after a 28-day fast, then again three days after the snakes ate a meal worth about a quarter of their body weight. Using an unbiased chemical scan of every detectable compound in the blood, they found more than 200 substances had shifted. One blew everything else off the chart: an unknown molecule that had increased more than 1,000-fold after eating.

Mass spectrometry, a standard lab tool for identifying molecules, confirmed the compound was pTOS, a chemically modified form of tyramine, which itself comes from the amino acid tyrosine. Tyrosine is found in everyday protein-rich foods: chicken, eggs, dairy, and soybeans. The researchers then synthesized a pure lab version of pTOS and confirmed it was an exact match for what appeared in the snake blood.

How pTOS Travels from Gut Bacteria to the Brain

Getting from a plate of food to a brain signal requires two steps. First, bacteria in the large intestine break down dietary tyrosine and convert it into tyramine. Then the liver adds a chemical modification that transforms tyramine into pTOS. When researchers knocked out the gut microbiome in pythons with a heavy course of antibiotics, the post-meal spike in pTOS was significantly reduced, confirming that gut bacteria are doing the essential first step.

In mice, pTOS proved far better at reaching the brain than tyramine alone. Tyramine cleared from the blood quickly and barely registered in brain tissue. pTOS, by contrast, was detectable in both the fluid surrounding the brain and in brain tissue itself within 30 minutes of injection. Once there, it activated a cluster of neurons in the ventromedial hypothalamus, a region of the brain that governs hunger and energy balance. When researchers genetically silenced those specific neurons, the appetite-reducing effect disappeared.

pTOS Reduced Food Intake and Body Weight in Obese Mice

Mice that received pTOS ate significantly less over 24 hours than untreated animals, roughly 18 percent less on average. The effect held in both lean and obese mice and worked whether pTOS was injected or swallowed.

Over 28 days of daily injections, obese mice ate less each day and ended the study roughly 9 percent lighter than untreated controls. Energy expenditure and physical activity were unaffected, suggesting the weight change came entirely from reduced food intake rather than increased calorie burning.

In these experiments, pTOS did not change blood sugar, blood pressure, or key hunger hormones including ghrelin, which signals the brain when the stomach is empty, and leptin, which signals fullness from fat tissue. Mice showed no signs of nausea or food aversion.

What pTOS Levels in Human Blood Could Mean for Obesity Treatment

Multiple human meal-test datasets showed that pTOS rises in the blood after eating, typically by two to five-fold. In one Norwegian study, a single participant’s levels jumped more than 30-fold after dinner. Researchers also directly measured blood from ten healthy men and found roughly a twofold rise in pTOS within an hour of eating.

In one cohort, people with prediabetes or type 2 diabetes did not show an increase after a meal. Whether a blunted pTOS response is a cause or a consequence of metabolic disease is unknown, but the pattern is intriguing and warrants further study.

One notable gap: pTOS was virtually undetectable in mouse blood under normal conditions, which is unusual given how clearly it appears in python and human samples. Researchers speculated that mice may produce a chemically similar stand-in that serves the same function, the way mice use corticosterone where humans use cortisol. It is a reasonable hypothesis, though it also means the mouse data may not fully capture how pTOS behaves in people.

Drugs like semaglutide, better known as Ozempic and Wegovy, work by mimicking GLP-1, a hormone released after eating that signals fullness. pTOS may act through a different pathway rather than the known hormone systems like GLP-1, acting on hunger-related neurons in the brain. Whether that distinction translates to a different safety or efficacy profile in humans is a question only clinical trials can answer. For now, the finding adds a genuinely new piece to a puzzle that researchers and patients alike have strong reasons to solve.

---